©The Author(s) 2025.
World J Gastrointest Oncol. Dec 15, 2025; 17(12): 112548
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.112548
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.112548
Table 3 Adverse events in 13 patients with advanced microsatellite stable/proficient mismatch repair colorectal included in this study, n (%)
| Adverse events | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
| Nausea | 0 | 2 (15.4) | 0 | 0 |
| Neutropenia | 3 (23.1) | 0 | 0 | 0 |
| Fatigue | 1 (7.7) | 1 (7.7) | 0 | 0 |
| Rash | 1 (7.7) | 1 (7.7) | 0 | 0 |
| Hypothyroidism | 1 (7.7) | 0 | 0 | 0 |
| Lower gastrointestinal hemorrhage | 0 | 0 | 1 (7.7) | 0 |
| Immune-related myocarditis | 0 | 1 (7.7) | 0 | 0 |
- Citation: Meng XY, Cai YM, Sun NN, Zhang WH, Cui RX, Zhang L, Zheng CC, Sun Z, Luo WX, Wang FW. Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer. World J Gastrointest Oncol 2025; 17(12): 112548
- URL: https://www.wjgnet.com/1948-5204/full/v17/i12/112548.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i12.112548